Key Takeaways GSK lifted its sales and earnings projections for the year, after a strong performance by its HIV and cancer drugs drove second-quarter sales higher. The British pharmaceutical firm said sales rose 13% year-over-year to 7.88 billion pounds ($10.12 billion), beating analysts' estimates. GSK said it expects sales growth between 7% and 9% this year, up from its prior forecast, but cut its vaccine sales outlook. GSK (GSK) lifted its sales and earnings projections for the year, after a strong perfo ...

This quarterly report represents an earnings surprise of 9%. A quarter ago, it was expected that this drug developer would post earnings of $0.94 per share when it actually produced earnings of $1.09, delivering a surprise of 15.96%. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. There are no easy answers to this key question, but one reliable measure that c ...

Collaboration brings together GSK disease area expertise and development capability with Flagship portfolio of 40+ bioplatform companies Initial phase to identify and accelerate promising scientific concepts for further research starting in respiratory and immunology GSK and Flagship to jointly fund up to $150 million upfront GSK and Flagship will initially fund up to $150 million upfront to support an exploration phase to identify the most promising concepts for further research and development with Flagsh ...

GSK, a multinational pharma company, scans as a bargain. Prior to Walmsley's tenure, GSK grappled with significant hurdles, including the patent expiration of its respiratory blockbuster Advair, a weak oncology portfolio, and a limited pipeline beyond respiratory medicines. During her seven-year tenure, GSK has emerged as a formidable player in infectious diseases, solidified its leadership in respiratory ailments, and made promising strides in hematology/oncology through strategic acquisitions. GSK's stock ...

Industry Overview - Pharmaceutical stocks are considered resilient investments due to the inelastic demand for medications and healthcare services, which remain stable regardless of economic conditions [1] - The U.S. economy is showing signs of slowing, with GDP growth at 1.4% year-over-year in Q1 2024, making it a favorable time to invest in undervalued pharma stocks [11] Novo Nordisk A/S (NVO) - Novo Nordisk is a Danish pharmaceutical company focused on diabetes and obesity care, as well as rare diseases, with significant media attention on its weight-loss drugs, Ozempic and Wegovy [3] - The company has generated billions in sales from its new drugs, with Goldman Sachs predicting the weight-loss drug market will reach $100 billion by 2030 [12] - NVO shares have increased by 80.4% over the past year, trading at 39.6x forward earnings, indicating strong potential for further growth [12] Novartis (NVS) - Novartis is a Swiss pharmaceutical company that develops drugs in therapeutic areas such as cardiovascular, immunology, and oncology, with Entresto being one of its most lucrative products [5][16] - In 2023, Novartis generated over $6 billion from Entresto, a 30% year-over-year increase, and $4.9 billion from Cosentyx, which treats moderate to severe hidradenitis suppurativa [16] - NVS shares trade at 14.2x forward earnings, making them relatively cheaper compared to other innovative companies in the U.S. stock market [17] GSK (GSK) - GSK is a British pharmaceutical company specializing in vaccines and general medicines, with a focus on respiratory, oncology, and infectious diseases [8] - Under CEO Emma Walmsley's leadership since 2017, GSK has shifted its strategy towards vaccines and cancer, moving away from its previous focus on HIV [18] - GSK generated $9.1 billion in Q1 revenue, driven by respiratory vaccines and specialty HIV products, and plans to launch 12 new pharma products by 2025 [18]

GSK plc (GSK) boasts a diversified base and presence in different geographical areas. The spin-off of the Consumer unit in 2022 has allowed it to focus on drug development. In July 2022, GSK de-merged its Consumer Healthcare segment into a standalone company. The independent Consumer Healthcare company was named Haleon (HLN) . Haleon was a consumer health joint venture, an over-the-counter medicines business, jointly created by GSK and partner Pfizer (PFE) in 2019. GSK has been regularly selling its stake i ...

WATERTOWN, Mass. and GOSSELIES, Belgium, July 08, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) ("iTeos"), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced the dosing of the first patient in GALAXIES Lung-301, a global, randomized, double-blind Phase 3 registrational clinical trial of belrestotug + dostarlimab versus placebo + pembrolizumab in patients with firstline advanc ...

Jemperli is currently approved for use in combination with standard-of-care chemotherapy combination, carboplatin and paclitaxel for treating adult patients with primary advanced or recurrent endometrial cancer that is either mismatch repair deficient or microsatellite instability-high in Europe. Shares of GSK have rallied 9.2% so far this year against the industry's decline of 5.8%. Jemperli is a key drug that aids GSK's oncology sales. The drug generated sales worth £80 million in the first quarter of 202 ...

Loading... Cantor projects around $1.1 billion of 5-year projected royalty revenues from GSK and initiates Innoviva with an Overweight rating. The company plans to expand Innoviva Specialty Therapeutics' product portfolio through organic and inorganic growth opportunities. Zoliflodacin could achieve over $500 million of annual peak sales in the U.S. Price Action: INVA shares are up 1.61% at $16.42 at last check Tuesday. Cantor Fitzgerald has initiated coverage on Innoviva, Inc. INVA, citing the company's un ...

GSK (GSK) announced that the FDA has approved the expanded use of its respiratory syncytial virus (RSV) vaccine, Arexvy for adults aged 50-59 who are at increased risk of RSV disease. Arexvy is currently approved in the United States, Europe, Japan and several other countries in adults aged 60 and more for the prevention of lower respiratory tract disease (LRTD) caused by RSV. With the latest approval, Arexvy becomes the first RSV vaccine approved for adults aged 50-59 who are at high risk. In the United St ...